COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01435616




Registration number
NCT01435616
Ethics application status
Date submitted
9/09/2011
Date registered
16/09/2011
Date last updated
13/04/2018

Titles & IDs
Public title
A Study in Patients With Type 2 Diabetes Mellitus
Scientific title
A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naive Patients With Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study
Secondary ID [1] 0 0
I2R-MC-BIAJ
Secondary ID [2] 0 0
12141
Universal Trial Number (UTN)
Trial acronym
IMAGINE 2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Glargine
Treatment: Drugs - LY2605541

Experimental: LY2605541 - LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC), once daily in combination with at least 2 pre-study oral antihyperglycemic medications (OAMs) prescribed by the personal physician, for 52 or 78 weeks

Active Comparator: Glargine - Glargine titrated based on blood glucose readings, administered SC, once daily in combination with at least 2 pre-study OAMs prescribed by the personal physician, for 52 or 78 weeks


Treatment: Drugs: Glargine


Treatment: Drugs: LY2605541


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline to 52 Week Endpoint in Hemoglobin A1c (HbA1c) - HbA1C is a test that measures a person's average blood glucose level over the past 2 to 3 months. Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) with baseline HbA1c measurement, stratification factors (country, low density lipoprotein-cholesterol [LDL-C, < 100 milligrams per deciliter {mg/dL} and = 100 mg/dL] and sulfonylurea [SU]/meglitinide use), visit, treatment, and visit-by-treatment interaction as fixed effects.
Timepoint [1] 0 0
Baseline, 52 weeks
Secondary outcome [1] 0 0
Rate of Total and Nocturnal Hypoglycemia Events - Hypoglycemia is a condition that occurs when a person's blood glucose level is lower than the normal range (less than or equal to 70 milligrams per deciliter [mg/dL] or less than 3.9 millimoles per liter [mmol/L]). Total hypoglycemia refers to an event that meets the criteria for documented symptomatic hypoglycemia, asymptomatic hypoglycemia, probable symptomatic hypoglycemia, unspecified hypoglycemia, or severe hypoglycemia. Nocturnal hypoglycemia refers to any total hypoglycemic event that occurs between bedtime and waking. Group mean (listed as LS means below) rates of total and nocturnal hypoglycemia were calculated using a negative binomial regression model (number of episodes = treatment + SU/meglitinide use + baseline hypoglycemia event rate, with log [exposure per 30 days] as the offset variable in the model).
Timepoint [1] 0 0
Baseline to 52 weeks
Secondary outcome [2] 0 0
Percentage of Participants With Hemoglobin A1c Equal or Less Than 6.5% and Less Than 7.0 % - The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Timepoint [2] 0 0
52 weeks
Secondary outcome [3] 0 0
Fasting Serum Glucose (By Laboratory Measurement) - LS means were calculated using a MMRM with baseline fasting serum glucose measurement, stratification factors (country, HbA1c, LDL-C [< 100 mg/dL and = 100 mg/dL], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [3] 0 0
52 weeks
Secondary outcome [4] 0 0
Fasting Blood Glucose (By Participant Self-monitored Blood Glucose Readings) - LS means were calculated using a MMRM with baseline fasting blood glucose measurement, stratification factors (country, HbA1c, LDL-C [< 100 mg/dL and = 100 mg/dL], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [4] 0 0
52 weeks
Secondary outcome [5] 0 0
6 Point Self-monitored Blood Glucose (SMBG) - Six-point SMBG profiles were obtained at pre-morning meal (fasting), pre-midday meal (lunch), pre-evening meal (dinner), bedtime, approximately 0300 hours, and pre-morning meal (fasting) the next day. Six-point SMBG profiles were obtained over 2 nonconsecutive days within the week prior to the next office visit. LS means were calculated using a MMRM with baseline blood glucose measurement, stratification factors (country, HbA1c, LDL-C [< 100 mg/dL and = 100 mg/dL], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [5] 0 0
52 weeks
Secondary outcome [6] 0 0
Change From Baseline to 52 Weeks in Body Weight - LS means were calculated using a MMRM with baseline body weight measurement, stratification factors (country, HbA1c, LDL-C [< 100 mg/dL and = 100 mg/dL], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [6] 0 0
Baseline, 52 weeks
Secondary outcome [7] 0 0
Hemoglobin A1c - HbA1c is a test that measures a person's average blood glucose level over the past 2 to 3 months. LS means were calculated using a MMRM with baseline HbA1C measurement, stratification factors (country, HbA1c, LDL-C [< 100 mg/dL and = 100 mg/dL], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [7] 0 0
52 weeks
Secondary outcome [8] 0 0
Insulin Dose Per Body Weight - LS means were calculated using a MMRM with baseline insulin dose measurement, stratification factors (country, HbA1c, LDL-C [< 100 mg/dL and = 100 mg/dL], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [8] 0 0
52 weeks
Secondary outcome [9] 0 0
Number of Insulin Dose Adjustments to Steady-State - Insulin doses were adjusted according to an algorithm (adapted from Riddle et al. 2003) during the first 26 weeks of the study and thereafter according to investigator judgment. Steady-state was defined as the first local maximum dose (maximum of moving 4-week interval) of LY2605541 or glargine within the window of +/- 2 weeks. The number of dose adjustments to steady-state was the total number of dose changes until steady-state was reached. LS means were calculated using a MMRM with baseline insulin dose measurement, stratification factors (country, HbA1c, LDL-C [< 100 mg/dL and = 100 mg/dL], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [9] 0 0
Baseline to 52 weeks
Secondary outcome [10] 0 0
European Quality of Life-5 Dimension (EQ-5D) - The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a 3-level scale of 1 to 3 (no problem, some problems, and extreme problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United States population-based algorithm. Scores range from -0.11 to 1.0, where a score of 1.0 indicates perfect health. LS means were calculated using a MMRM with baseline stratification factors (country, HbA1c, and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [10] 0 0
52 weeks
Secondary outcome [11] 0 0
Insulin Treatment Satisfaction Questionnaire - The Insulin Treatment Satisfaction Questionnaire (ITSQ) is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes who are receiving insulin. The questionnaire measures satisfaction from the following 5 domains: inconvenience of regimen, lifestyle flexibility, glycemic control, hypoglycemic control, and insulin delivery device. Data presented are the transformed total score on a scale of 0 to 100, where higher scores indicate better treatment satisfaction. LS means were calculated using a MMRM with stratification factors (country, HbA1c, and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [11] 0 0
Up to 52 weeks
Secondary outcome [12] 0 0
Adult Low Blood Sugar Survey - The adult Low Blood Sugar Survey (LBSS) is a validated, participant-reported 33-item questionnaire with items rated on a 5-point Likert scale, where 0 = never and 4 = always. The LBSS measures behaviors to avoid hypoglycemia and its negative consequences (15 items) and worries about hypoglycemia and its negative consequences (18 items). Total score is the sum of all items (range of 0 to 132). Higher total scores reflect greater fear of hypoglycemia. LS means were calculated using an analysis of covariance model (ANCOVA) with baseline LBSS score, stratification factors (country, HbA1c, and SU/meglitinide use), and treatment as fixed effects.
Timepoint [12] 0 0
Up to 52 weeks
Secondary outcome [13] 0 0
Change From Baseline to 52 Weeks in Triglycerides, Low Density Lipoprotein Cholesterol (LDL-C), and High Density Lipoprotein Cholesterol (HDL-C) - LS means were calculated using a MMRM with baseline lipid measurement, stratification factors (country, HbA1c, LDL-C [< 100 mg/dL and = 100 mg/dL], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [13] 0 0
Baseline, 52 weeks
Secondary outcome [14] 0 0
Percentage of Participants With Equal or Above 2-, and 3-fold Upper Limits of Normal (ULN) for Total Bilirubin
Timepoint [14] 0 0
Up to 52 weeks
Secondary outcome [15] 0 0
Overall Treatment-Emergent Anti-LY2065541 Antibody Response (TEAR) - The percentage of participants with a TEAR is summarized. TEAR is defined as a change in the anti-LY2605541 antibody level from undetectable at baseline to detectable at baseline, or, for those participants with detectable antibodies at baseline, change to a value with at least a 130% relative increase from baseline. Overall TEAR is defined as one or more TEAR during the specified period.
Timepoint [15] 0 0
Baseline to 78 weeks
Secondary outcome [16] 0 0
Intra-participant Variability of the Fasting Blood Glucose (FBG) - Intra-participant variability of FBG, which was measured by SMBG, was assessed by the standard deviation of the FBG measurement at the Week 52 visit. LS means were calculated using a MMRM with baseline fasting blood glucose measurement, stratification factors (country, HbA1c, LDL-C [< 100 mg/dL and = 100 mg/dL], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Timepoint [16] 0 0
52 weeks
Secondary outcome [17] 0 0
Percentage of Participants With Total and Nocturnal Hypoglycemic Events - A hypoglycemic event is defined by a blood glucose value =70 mg/dL (3.9mmol/L). Total hypoglycemic events include documented symptomatic hypoglycemia, asymptomatic hypoglycemia, probable symptomatic hypoglycemia, unspecified hypoglycemia, or severe hypoglycemia. Nocturnal hypoglycemic events refer to any total hypoglycemic event that occurs between bedtime and waking. The percentage of participants was calculated by dividing the number of participants with hypoglycemic or nocturnal hypoglycemic events by the total number of participants analyzed, multiplied by 100.
Timepoint [17] 0 0
Baseline to 52 weeks
Secondary outcome [18] 0 0
Percentage of Participants With HbA1C Equal or Less Than 6.5% and Less Than 7.0 % and Without Nocturnal Hypoglycemia - The percentage of participants with HbA1C = 6.5% or < 7.0% without nocturnal hypoglycemia is presented. Percentage was calculated by dividing the number of participants with the indicated HbA1c values over the total number of participants and multiplying by 100.
Timepoint [18] 0 0
Up to 52 weeks
Secondary outcome [19] 0 0
Percentage of Participants With Equal or Above 2- and 3-fold ULN for Alanine Transaminase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) and Aspartate Transaminase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) - The percentage of participants was calculated by dividing the number of participants equal or above 2- or 3-fold ULN for ALT/SGPT or AST/SGOT by the total number of participants analyzed, multiplied by 100.
Timepoint [19] 0 0
Up to 52 weeks

Eligibility
Key inclusion criteria
- Have type 2 diabetes mellitus, not treated with insulin, for at least 1 year prior to
the study

- Have been receiving at least 2 OAMs for at least 3 months before entering the study

- Have a hemoglobin A1c (HbA1c) value between 7.0% and 11.0%, inclusive, at screening

- Are capable of and willing to inject insulin with a vial and syringe and perform self
blood glucose monitoring

- Women of childbearing potential only: are not breastfeeding, have a negative pregnancy
test at the time of screening and randomization, intend to not become pregnant during
the trial, have practiced a reliable method of birth control for at least 6 weeks
prior to screening, and agree to use a reliable method of birth control during the
study and until 2 weeks following the last dose of study drug
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Have used insulin therapy (outside of pregnancy) anytime in the past 2 years, except
for short-term treatment of acute conditions, and up to a maximum of 4 continuous
weeks

- Use of rosiglitazone, pramlintide, or glucagon-like peptide 1 (GLP-1) receptor agonist
(for example, exenatide, exenatide once weekly, or liraglutide) concurrently or within
3 months prior to screening

- Are currently taking, or have taken within the 3 months preceding screening,
medications to promote weight loss

- Have had any episodes of severe hypoglycemia within 6 months prior to screening

- Have had 1 or more episodes of ketoacidosis or hyperosmolar state/coma in the 6 months
prior to the study

- Have cardiac disease with functional status that is New York Heart Association Class
III or IV (per New York Heart Association [NYHA] Cardiac Disease Classification)

- Have a history of renal transplantation, or are currently receiving renal dialysis or
have serum creatinine greater or equal than 2 milligrams per deciliter (mg/dL)

- Have obvious clinical signs or symptoms of liver disease (excluding non- alcoholic
fatty liver disease [NAFLD]), acute or chronic hepatitis, non-alcoholic
steatohepatitis (NASH), or elevated liver enzyme measurements at screening

- Have had a blood transfusion or severe blood loss within 3 months prior to screening
or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other
traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c

- Have active or untreated malignancy or have been in remission from clinically
significant malignancy for less than 5 years

- Have fasting or non-fasting triglycerides greater than 400 mg/dL (greater than 4.5
millimoles per liter [mmol/L]) at screening

- Are using lipid-lowering medication at a dose that has not been stable for 90 days
prior to screening

- Are using niacin preparations as a lipid lowering medication and bile acid
sequestrants within 90 days prior to screening

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Merewether
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Keswick
Recruitment hospital [3] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Box Hill
Recruitment hospital [4] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Fremantle
Recruitment postcode(s) [1] 0 0
2291 - Merewether
Recruitment postcode(s) [2] 0 0
5035 - Keswick
Recruitment postcode(s) [3] 0 0
3128 - Box Hill
Recruitment postcode(s) [4] 0 0
6160 - Fremantle
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Hawaii
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maine
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Montana
Country [17] 0 0
United States of America
State/province [17] 0 0
New Hampshire
Country [18] 0 0
United States of America
State/province [18] 0 0
New Jersey
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Utah
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
Argentina
State/province [27] 0 0
Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Caba
Country [29] 0 0
Argentina
State/province [29] 0 0
Córdoba
Country [30] 0 0
Argentina
State/province [30] 0 0
Mar Del Plata
Country [31] 0 0
Brazil
State/province [31] 0 0
Marilia
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio De Janeiro
Country [33] 0 0
Brazil
State/province [33] 0 0
Setor Oeste/Goiania
Country [34] 0 0
Brazil
State/province [34] 0 0
São Paulo
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
British Columbia
Country [37] 0 0
Canada
State/province [37] 0 0
Manitoba
Country [38] 0 0
Canada
State/province [38] 0 0
Ontario
Country [39] 0 0
Canada
State/province [39] 0 0
Quebec
Country [40] 0 0
Finland
State/province [40] 0 0
Oulu
Country [41] 0 0
Finland
State/province [41] 0 0
Seinajoki
Country [42] 0 0
Germany
State/province [42] 0 0
Dippoldiswalde
Country [43] 0 0
Germany
State/province [43] 0 0
Dresden
Country [44] 0 0
Germany
State/province [44] 0 0
Friedrichsthal
Country [45] 0 0
Germany
State/province [45] 0 0
Furth Im Wald
Country [46] 0 0
Germany
State/province [46] 0 0
Goch
Country [47] 0 0
Germany
State/province [47] 0 0
Hamburg
Country [48] 0 0
Germany
State/province [48] 0 0
Ludwigshafen
Country [49] 0 0
Germany
State/province [49] 0 0
Münster
Country [50] 0 0
Germany
State/province [50] 0 0
Saarbrücken
Country [51] 0 0
Germany
State/province [51] 0 0
Schweinfurt
Country [52] 0 0
Germany
State/province [52] 0 0
Sulzbach
Country [53] 0 0
Greece
State/province [53] 0 0
Ampelokipoi
Country [54] 0 0
Greece
State/province [54] 0 0
Athens
Country [55] 0 0
Greece
State/province [55] 0 0
Thessaloniki
Country [56] 0 0
Hungary
State/province [56] 0 0
Budapest
Country [57] 0 0
Hungary
State/province [57] 0 0
Debrecen
Country [58] 0 0
Hungary
State/province [58] 0 0
Mako
Country [59] 0 0
Hungary
State/province [59] 0 0
Salgotarjan
Country [60] 0 0
Hungary
State/province [60] 0 0
Sopron
Country [61] 0 0
Israel
State/province [61] 0 0
Beer Sheva
Country [62] 0 0
Israel
State/province [62] 0 0
Haifa
Country [63] 0 0
Israel
State/province [63] 0 0
Raanana
Country [64] 0 0
Italy
State/province [64] 0 0
Carpi
Country [65] 0 0
Italy
State/province [65] 0 0
Castellanza
Country [66] 0 0
Italy
State/province [66] 0 0
Foggia
Country [67] 0 0
Italy
State/province [67] 0 0
Forli
Country [68] 0 0
Italy
State/province [68] 0 0
Rome
Country [69] 0 0
Italy
State/province [69] 0 0
Sesto San Giovanni
Country [70] 0 0
Lithuania
State/province [70] 0 0
Utena
Country [71] 0 0
Lithuania
State/province [71] 0 0
Vilnius
Country [72] 0 0
Mexico
State/province [72] 0 0
Coatzacoalcos
Country [73] 0 0
Mexico
State/province [73] 0 0
Mexico City
Country [74] 0 0
Mexico
State/province [74] 0 0
Monterrey
Country [75] 0 0
New Zealand
State/province [75] 0 0
Auckland
Country [76] 0 0
Poland
State/province [76] 0 0
Kamieniec Zabkowicki
Country [77] 0 0
Poland
State/province [77] 0 0
Katowice
Country [78] 0 0
Poland
State/province [78] 0 0
Krakow
Country [79] 0 0
Poland
State/province [79] 0 0
Lodz
Country [80] 0 0
Poland
State/province [80] 0 0
Ruda Slaska
Country [81] 0 0
Poland
State/province [81] 0 0
Szczecin
Country [82] 0 0
Poland
State/province [82] 0 0
Tychy
Country [83] 0 0
Poland
State/province [83] 0 0
Warsaw
Country [84] 0 0
Puerto Rico
State/province [84] 0 0
Hato Rey
Country [85] 0 0
Puerto Rico
State/province [85] 0 0
Manati
Country [86] 0 0
Puerto Rico
State/province [86] 0 0
San Juan
Country [87] 0 0
Romania
State/province [87] 0 0
Bucharest
Country [88] 0 0
Romania
State/province [88] 0 0
Cluj-Napoca
Country [89] 0 0
Romania
State/province [89] 0 0
Iasi
Country [90] 0 0
Romania
State/province [90] 0 0
Oradea
Country [91] 0 0
Romania
State/province [91] 0 0
Ploiesti
Country [92] 0 0
Romania
State/province [92] 0 0
Resita
Country [93] 0 0
Romania
State/province [93] 0 0
Targu-Mures
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Cheboksary
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Kazan
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Kursk
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Novosibirsk
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Saint Petersburg
Country [99] 0 0
Slovakia
State/province [99] 0 0
Bratislava
Country [100] 0 0
Slovakia
State/province [100] 0 0
Sala
Country [101] 0 0
Slovakia
State/province [101] 0 0
Vranov Nad Toplou
Country [102] 0 0
South Africa
State/province [102] 0 0
Paarl
Country [103] 0 0
South Africa
State/province [103] 0 0
Parow
Country [104] 0 0
South Africa
State/province [104] 0 0
Somerset West
Country [105] 0 0
Spain
State/province [105] 0 0
Alicante
Country [106] 0 0
Spain
State/province [106] 0 0
Cordoba
Country [107] 0 0
Spain
State/province [107] 0 0
Pozuelo De Alarcon
Country [108] 0 0
Spain
State/province [108] 0 0
Requena
Country [109] 0 0
Spain
State/province [109] 0 0
Seville
Country [110] 0 0
Spain
State/province [110] 0 0
Toledo
Country [111] 0 0
Turkey
State/province [111] 0 0
Gaziantep
Country [112] 0 0
Turkey
State/province [112] 0 0
Hatay
Country [113] 0 0
Turkey
State/province [113] 0 0
Izmir
Country [114] 0 0
Turkey
State/province [114] 0 0
Kayseri
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Berks
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Leicestershire
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Surrey
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Wales

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is:

- To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of
treatment.

- To compare the rate of night time low blood sugar episodes on LY2605541 with insulin
glargine during 52 weeks of treatment.

- To compare the number of participants on LY2605541 reaching blood sugar targets without
low blood sugar episodes at night to those taking insulin glargine after 52 weeks of
treatment.

- To compare the rate of low blood sugar episodes on LY2605541 with insulin glargine after
52 weeks of treatment
Trial website
https://clinicaltrials.gov/show/NCT01435616
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications